论文部分内容阅读
早期使用血栓溶解剂(链激酶或尿激酶)可能会使因血管闭塞所致的急性心肌梗塞的程度受到限制,并由此而改善心肌功能。本文对有关的临床试验作一综述,并对各组的试验设计进行评论。各试验组的结果见附表。资料表明,各组在治疗开始时的症状持续时间、观察期限、链激酶的剂量与疗程、对照组用药以及采用的随机化方法等方面,均存在差异。西德-瑞士组第一次试验在设计上存在严重的缺点,由此而产生的选择病例的偏性影响了对疗效的判断。西德-瑞士组
Early use of thrombolytics (streptokinase or urokinase) may limit the extent of acute myocardial infarction due to vascular occlusion and thereby improve myocardial function. This article reviews the clinical trials involved and comments on the trial design of each group. The results of each test group see schedule. Data show that the treatment group at the beginning of the symptoms duration, observation period, the dose and course of streptokinase, the control group medication and the use of randomized methods and so on, there are differences. The first trial in the West Germany-Switzerland group was designed with serious shortcomings and the resulting bias in selected cases affected the judgment of efficacy. West Germany - Switzerland group